TSH RECEPTOR ANTIBODIES

The TSH Receptor Antibodies test measures autoantibodies directed against the Thyroid-Stimulating Hormone receptor. These antibodies are commonly known as TRAb or thyrotropin-receptor antibodies. They are closely associated with Graves disease, an autoimmune condition that commonly causes an overactive thyroid gland.

The TSH receptor is located on thyroid cells and normally responds to TSH produced by the pituitary gland. In Graves disease, the immune system produces antibodies that bind to this receptor. Stimulating antibodies can activate the receptor independently of normal pituitary control, causing the thyroid to produce excessive amounts of T3 and T4.

A TRAb binding assay may detect both antibodies that stimulate the receptor and antibodies that block it. Therefore, the result must be interpreted with thyroid-function tests, symptoms and clinical history. The test is different from a routine TSH measurement and from thyroid-peroxidase or thyroglobulin antibody tests.

Benefits of the Test

• Supports diagnosis of Graves disease and autoimmune hyperthyroidism.
• Helps distinguish Graves disease from other causes of thyrotoxicosis.
• May be useful when a radioactive iodine uptake scan is unsuitable or unavailable.
• Can support assessment of the likelihood of Graves disease recurrence.
• May help doctors decide whether antithyroid treatment can be discontinued.
• Supports risk assessment during pregnancy in women with current or previous Graves disease.
• Helps evaluate the possibility of fetal or neonatal thyroid dysfunction in selected pregnancies.
• Can provide useful information when thyroid-function results and clinical findings are unclear.

Why Doctors Recommend This Test

A doctor may recommend TRAb testing when symptoms and thyroid-function results suggest Graves disease. Symptoms of hyperthyroidism may include unexplained weight loss, rapid or irregular heartbeat, tremors, sweating, heat intolerance, anxiety, muscle weakness, frequent bowel movements and difficulty sleeping.

Graves disease may also cause an enlarged thyroid gland, eye symptoms or skin changes. A positive TRAb result in the correct clinical setting strongly supports an autoimmune cause of hyperthyroidism. The test can be particularly helpful when the physical signs of Graves disease are absent or unclear.

Not every case of thyrotoxicosis is caused by Graves disease. Other possible causes include thyroiditis, toxic thyroid nodules, excess thyroid medication and temporary pregnancy-related thyroid changes. TRAb testing may help distinguish Graves disease from these conditions.

Doctors may repeat the test during or after antithyroid treatment. Persistent or elevated TRAb can indicate continuing autoimmune activity and may be associated with a greater likelihood of recurrence after medicine is stopped. Treatment decisions should not be based on the antibody result alone.

TRAb testing has an important role in selected pregnancies. These antibodies are immunoglobulin G antibodies and can cross the placenta. High levels in a pregnant woman with active or previous Graves disease may affect the baby's thyroid and increase the risk of fetal or neonatal thyroid dysfunction.

Pregnancy-related testing may be necessary even if the mother previously received thyroid surgery or radioactive iodine and is currently taking thyroid-hormone replacement. Graves-related antibodies can persist after thyroid treatment because surgery and radioactive iodine do not directly remove the underlying autoimmune process.

Preparation Before Test

Fasting is generally not required for the TSH Receptor Antibodies test unless other blood tests ordered at the same time require fasting. Follow the specific instructions provided by the doctor or laboratory.

Inform the doctor about antithyroid medicines, levothyroxine, previous radioactive iodine therapy, thyroid surgery, steroids, immune-modifying treatment, biotin supplements and all other medicines or supplements. Do not discontinue any prescribed treatment without medical advice.

Tell the healthcare professional if you are pregnant, planning pregnancy or have previously been treated for Graves disease. The pregnancy week and treatment history are important because the doctor may schedule testing at specific stages of pregnancy.

Provide information about recent thyroid-function results, thyroid imaging, eye symptoms and previous TRAb or TSI measurements. Results from different assay types or laboratories may not be directly comparable.

A healthcare professional collects a blood sample from a vein, usually in the arm. The procedure generally takes only a few minutes. Serum is commonly used for laboratory analysis.

Normal Reporting Time

The TSH Receptor Antibodies report is commonly available within approximately 2–5 working days after the laboratory receives a suitable sample. The precise turnaround time may vary according to the testing schedule, sample transport, analytical method, quality-control checks and result verification.

Who Should Take This Test?

This test may be appropriate for patients with a suppressed TSH, elevated thyroid hormones or symptoms suggesting Graves disease. It may also be requested when the cause of hyperthyroidism remains unclear after routine thyroid-function testing.

Patients receiving antithyroid medicines may undergo TRAb testing when the doctor is assessing disease activity, treatment response or the possibility of relapse after treatment withdrawal.

Pregnant women with active Graves disease, a previous history of Graves disease or previous thyroid ablation may require TRAb measurement according to specialist advice. An elevated result may lead to closer maternal, fetal and neonatal monitoring.

The test is not generally required for every patient with hypothyroidism or every abnormal TSH result. A physician or endocrinologist should determine whether TRAb testing is clinically appropriate.

Detailed Information

TSH receptor autoantibodies are not all functionally identical. Stimulating antibodies activate the receptor and increase thyroid-hormone production. Blocking antibodies prevent normal TSH action and may contribute to hypothyroid patterns. Some patients may have a mixture of antibody activities.

Many TRAb laboratory methods are competitive binding assays. They detect antibodies that interfere with the binding of a labelled antibody to the TSH receptor. A standard TRAb result may therefore indicate receptor-binding antibodies without separately identifying whether their functional effect is stimulating or blocking.

Thyroid-Stimulating Immunoglobulin, or TSI, is closely related but not identical to a general TRAb measurement. TSI assays are designed to identify stimulating antibody activity more specifically, while many TRAb assays detect both stimulating and blocking receptor antibodies.

TRAb is also different from anti-TPO and anti-thyroglobulin antibodies. Anti-TPO antibodies are commonly associated with Hashimoto thyroiditis and autoimmune hypothyroidism, although they may also occur in Graves disease. TRAb is more closely connected to the mechanism of Graves hyperthyroidism.

A positive TRAb result supports Graves disease in the appropriate clinical setting but should not be interpreted independently. A negative result reduces the likelihood but may not exclude every case, particularly when antibody concentrations are low or the disease is mild.

Results are commonly interpreted with TSH, free T4, T3, clinical examination and, when appropriate, thyroid ultrasound or nuclear-medicine imaging. During pregnancy, interpretation also considers gestational age, treatment history and fetal monitoring findings.

Reference limits and units vary according to the assay. Results should be interpreted using the cut-off printed on the laboratory report and reviewed by an endocrinologist, physician or pregnancy-care specialist familiar with the patient's thyroid history.